Loading organizations...
Precipio Diagnostics is a technology company.
Precipio Diagnostics develops and commercializes advanced diagnostic solutions for cancer, focusing on improving accuracy in oncology. The company provides a comprehensive platform that includes specialized hematopathology and molecular assays, designed to detect and characterize various cancers more precisely. Their technical approach integrates proprietary technologies and expert analysis to address diagnostic challenges and reduce the potential for misdiagnosis.
The company was founded in 2011 by Ilan Danieli, who serves as CEO, and Zaki Sabet, who is the Chief Operating Officer. Their foundational insight stemmed from the pervasive problem of misdiagnosis in cancer, leading them to build a platform dedicated to eradicating this issue by harnessing specialized expertise and technology. Both founders brought prior experience in management and laboratory operations, respectively, to the nascent organization.
Pathologists, oncologists, and other healthcare providers utilize Precipio's diagnostic products and services for precise cancer identification and informed treatment planning. The company also engages in collaborations with academic institutions to further its diagnostic capabilities. Precipio’s long-term vision centers on elevating the standard of cancer care globally by ensuring diagnostic integrity, thereby driving better clinical decisions and ultimately improving patient outcomes.
Precipio Diagnostics has raised $2.0M across 1 funding round.
Precipio Diagnostics has raised $2.0M in total across 1 funding round.
Precipio Diagnostics (Precipio, Inc.) is a clinical diagnostics company that builds specialized hematopathology testing platforms and technologies aimed at improving accuracy and throughput for blood-cancer diagnosis and related molecular testing[2][3].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Healthcare Landscape
Quick Take & Future Outlook
Quick take: Precipio is a specialist hematopathology diagnostics company that differentiates itself through proprietary testing technologies and an academic‑leaning clinical model aimed at reducing cancer diagnostic errors; its future influence will hinge on clinical validation, reimbursement, and successful scale‑up of its testing services and technologies[2][1].[2]
Precipio Diagnostics has raised $2.0M in total across 1 funding round.
Precipio Diagnostics's investors include Connecticut Innovations, Enhanced Capital, Ironwood Capital, Kuzari Group.
Precipio Diagnostics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Series B in October 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2013 | $2.0M Series B | Connecticut Innovations, Enhanced Capital, Ironwood Capital, Kuzari Group |